# Safety and Efficacy Study of Autologous Cultured Adipose -Derived Stem Cells for the Crohn's Fistula

> **NCT01011244** · PHASE2 · COMPLETED · sponsor: **Anterogen Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Crohn's Fistula

## Interventions

- **BIOLOGICAL:** ADIPOPLUS

## Key facts

- **NCT ID:** NCT01011244
- **Lead sponsor:** Anterogen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2012-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01011244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01011244, "Safety and Efficacy Study of Autologous Cultured Adipose -Derived Stem Cells for the Crohn's Fistula". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01011244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*